Erratum to “CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma” [Eur Urol 2017;72:962–71] (S0302283817300994) (10.1016/j.eururo.2017.02.010))

  1. Escudier, B.
  2. Sharma, P.
  3. McDermott, D.F.
  4. George, S.
  5. Hammers, H.J.
  6. Srinivas, S.
  7. Tykodi, S.S.
  8. Sosman, J.A.
  9. Procopio, G.
  10. Plimack, E.R.
  11. Castellano, D.
  12. Gurney, H.
  13. Donskov, F.
  14. Peltola, K.
  15. Wagstaff, J.
  16. Gauler, T.C.
  17. Ueda, T.
  18. Zhao, H.
  19. Waxman, I.M.
  20. Motzer, R.J.
Aldizkaria:
European Urology

ISSN: 1873-7560 0302-2838

Argitalpen urtea: 2018

Alea: 73

Zenbakia: 4

Orrialdeak: e116-e118

Mota: Hutsen zuzenketa

DOI: 10.1016/J.EURURO.2017.12.016 GOOGLE SCHOLAR